Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
Launched by FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY · Dec 8, 2016
Trial Information
Current as of May 27, 2025
Unknown status
Keywords
ClinConnect Summary
The investigators plan to measure routine laboratory parameters of coagulation and fibrinolysis, the procoagulant or profibrinolytic activity of microparticles (MPs), and explore the role of the procoagulant and profibrinolytic activating factor of MPs in the pathogenesis of coagulopathy in patients with APL.
i. Dynamic turbidimetry of plasma clot formation. The effects of MPs on the kinetics of fibrin formation and on the optical properties of clots are studied using dynamic turbidimetry of re-calcified plasma samples (platelet-free plasma and microparticle-depleted plasma) without adding...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with de novo APL accompanied by hemorrhage.
- • The diagnosis was confirmed by the presence of t(15;17) and/or the PML (promyelocytic leukemia)/RARa(retinoic acid receptor alpha) fusion gene.
- • Patients should receive single-agent arsenic trioxide (ATO) for induction therapy.
- Exclusion Criteria:
- • Patients with relapsed acute promyelocytic leukemia.
- • Patients without evidence of bleeding.
- • Patients younger than 18 years.
About First Affiliated Hospital Of Harbin Medical University
The First Affiliated Hospital of Harbin Medical University is a leading clinical research institution dedicated to advancing healthcare through innovative medical studies and trials. As a prominent teaching hospital in China, it combines cutting-edge research with comprehensive patient care, facilitating a robust environment for clinical investigations across various medical disciplines. The hospital is committed to improving clinical outcomes and enhancing patient safety, fostering collaboration among healthcare professionals, researchers, and industry partners. With a focus on translating research findings into practice, the First Affiliated Hospital plays a vital role in the development of new treatments and therapies, contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Harbin, Heilongjiang, China
Patients applied
Trial Officials
Jin Zhou, MD, PhD
Study Chair
First Affiliated Hospital of Harbin Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials